Mourad Hamimed

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Combined Docetaxel-Loaded Perfluorocarbon Nanodroplets with Ultrasound-Mediated Blood-Brain Barrier Disruption for Effective Glioblastoma Treatment in Mice Model.

Combined Docetaxel-Loaded Perfluorocarbon Nanodroplets with Ultrasound-Mediated Blood-Brain Barrier Disruption for Effective Glioblastoma Treatment in Mice Model.

Journal: International journal of nanomedicine

Published: November 04, 2025

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: September 12, 2025

Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.

Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.

Journal: CPT: pharmacometrics & systems pharmacology

Published: August 25, 2023

Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?

Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?

Journal: Cancer chemotherapy and pharmacology

Published: July 15, 2023

Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.

Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.

Journal: British journal of haematology

Published: April 07, 2023

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.

Journal: ESMO open

Published: August 25, 2022

Perfluorocarbon Nanodroplets as Potential Nanocarriers for Brain Delivery Assisted by Focused Ultrasound-Mediated Blood-Brain Barrier Disruption.

Perfluorocarbon Nanodroplets as Potential Nanocarriers for Brain Delivery Assisted by Focused Ultrasound-Mediated Blood-Brain Barrier Disruption.

Journal: Pharmaceutics

Published: June 08, 2022

Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.

Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.

Journal: Cancer chemotherapy and pharmacology

Published: January 31, 2022

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 03, 2021

Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351.

Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: June 26, 2021

Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma.

Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma.

Journal: British journal of clinical pharmacology

Published: June 21, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026